Factors that are driving the market's growth include huge investments in microbiome research, a rise in the demand for NGS services and a surge in genomic research, and the widening application area of microbiome sequencing.
NGS technologies exhibit a paradigm shift in sequencing capabilities. This expertise has been extensively applied to biological research, resulting in significant and remarkable insights into the molecular biology of cells.
Over the past decade, budgets allocated to R&D have increased steadily. The pharmaceutical companies want their drugs to perform well. However, a huge cost is involved in developing such drugs, and immense funding is required to market these drugs. The most critical steps in the drug discovery process of pharmaceutical companies are target identification and single nucleotide polymorphisms (SNPs), which are broadly used to analyze individual characteristics for target identification.
NGS is improving the resolution of bacterial species identification, with the use of various identification methods. Thus, the rising demand for NGS services in various biological sectors is spurring the growth of the market. Additionally, many companies are concentrating on novel exome sequencing and RNA sequencing applications, in niche market segments.
Key Market Trends
Application in Cancer/Oncology is Expected to a Register a High Growth Rate
There is increasing evidence that microbiota like gut microbiota contributes to the carcinogenesis of colorectal cancer (CRC), along with genetic and other factors. For instance, a 2020 report by Wanxin Liu et al., published in BioMed Research International Journal showed the role of gut microbiota in CRC in the Chinese population using 16SrRNA Sequencing. The intestinal flora is more like one of our organs, providing a new pathway for therapeutic intervention as well as a part of the immune system, supporting the host to promote health or initiate disease. Microbiota, associated with the human body, also play a role in shaping the inflammatory environment and promoting tumor growth and spread.
As a result, the demand for research and applications of microbiome sequencing in the field of cancer is increasing. Moreover, the demand for these services has also increased to increasing the incidence of CRC globally. As per a 2019 report by the International Agency for Research on Cancer, the incidence of colon cancer is expected to increase from nearly 1.1 million in 2019 to over 1.5 million by 2030. Hence all these factors are helpful in the overall market growth.
North America Dominates the Market and is Expected to do so during the Forecast Period
The North American region, especially the United States, has the most active ecosystems for genomic research, which is supported by both the government and the industry players. The US government supports genomics research through various government bodies, like NHGRI (National Human Genome Research Institute, the United States), which support the work on sequencing of the human genome, and fund research on the genome's structure, function, and role in health and disease.
The presence of a conducive research environment for genomic exploration, which is supported by adequate government funding and industry support, ensures the growth of the market for microbiome sequencing services in North America, over the forecast period.
The global microbiome sequencing services market is moderately competitive and consists of a number of major players. Companies, like Baseclear BV, Clinical Microbiomics AS, Merieux Nutrisciences Corporations, EPIBIOME, Microbiome Insights Inc., Microbiome Therapeutics LLC, MR DNA, Second Genome, Ubiome Inc., and Zymo Research Corp., among others, hold substantial shares in the microbiome sequencing services market.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support